Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9789182
SERIAL NO

14437029

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Provided are methods for clinical treatment of cancer (e.g., solid tumors or hematological malignancies) using an anti-KIR antibody in combination with an anti-CTLA-4 antibody.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
INNATE PHARMAMARSEILLE FRANCE MARSEILLE BOUCHES-DU-RHONE

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Andre, Pascale Marseilles, FR 31 339
Graziano, Robert F Frenchtown, US 14 197
Gupta, Ashok K Clarksburg, US 45 1357
Kim, Su Young Belle Mead, US 18 100
Wigginton, Jon Collegeville, US 5 50

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Apr 17, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Apr 17, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00